Ftse Mib
35.366,20
0,61%
DAX
18.869,36
0,78%
S&P 500
5.308,15
1,17%
NASDAQ
16.742,39
1,40%
Bitcoin
65.899,35
-0,54%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. USOTC Genmab A S (PK) (GNMSF) Genmab A S (PK) (GNMSF) Notizie

GNMSF

Genmab A S (PK) (GNMSF)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:USOTC:GNMSF
DataOraFonteTitoloSimboloCompagnia
08/05/202418:46Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]USOTC:GNMSFGenmab A S (PK)
10/06/202013:34Edgar (US Regulatory)Report of Foreign Issuer (6-k)USOTC:GNMSFGenmab A S (PK)
30/03/202023:16Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)USOTC:GNMSFGenmab A S (PK)
07/02/202014:56Edgar (US Regulatory)Statement of Ownership (sc 13g)USOTC:GNMSFGenmab A S (PK)
14/08/201915:27Edgar (US Regulatory)Unknown (sec Staff)USOTC:GNMSFGenmab A S (PK)
19/07/201912:02Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(4) (424b4)USOTC:GNMSFGenmab A S (PK)
18/07/201915:32Edgar (US Regulatory)Securities Registration (ads, Immediate) (f-6ef)USOTC:GNMSFGenmab A S (PK)
18/07/201912:01Edgar (US Regulatory)Notice of Effectiveness (effect)USOTC:GNMSFGenmab A S (PK)
18/07/201901:56Edgar (US Regulatory)Registration of Additional Securities (up to 20%, Foreign Issuer) (f-1mef)USOTC:GNMSFGenmab A S (PK)
17/07/201923:25Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)USOTC:GNMSFGenmab A S (PK)
16/07/201914:55Edgar (US Regulatory)Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)USOTC:GNMSFGenmab A S (PK)
16/07/201914:06Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1/a)USOTC:GNMSFGenmab A S (PK)
15/07/201923:02Edgar (US Regulatory)Post-effective Amendment to a Previously Filed F-6. (f-6 Pos)USOTC:GNMSFGenmab A S (PK)
15/07/201920:38Edgar (US Regulatory)Certification by the Exchange Approving Securities for Listing (cert)USOTC:GNMSFGenmab A S (PK)
12/07/201922:53Edgar (US Regulatory)Securities Registration (section 12(b)) (8-a12b)USOTC:GNMSFGenmab A S (PK)
28/05/201922:29Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1)USOTC:GNMSFGenmab A S (PK)
31/07/201420:50GlobeNewswire Inc.GSK and Genmab Announce Positive Interim Result for Phase III Study of Ofatumumab as Maintenance Therapy for Relapsed CLLUSOTC:GNMSFGenmab A S (PK)
23/07/201413:11GlobeNewswire Inc.Second Quarter 2014 Net Sales Figures for Arzerra(r)USOTC:GNMSFGenmab A S (PK)
18/07/201415:18GlobeNewswire Inc.Genmab Announces Phase III Study of Daratumumab in Front Line Multiple MyelomaUSOTC:GNMSFGenmab A S (PK)
14/07/201415:59GlobeNewswire Inc.Genmab to Receive Milestone Payment in DuoBody Platform Collaboration with JanssenUSOTC:GNMSFGenmab A S (PK)
07/07/201416:23GlobeNewswire Inc.Genmab Reaches USD 25 Million Milestone in Daratumumab Collaboration with JanssenUSOTC:GNMSFGenmab A S (PK)
03/07/201415:38GlobeNewswire Inc.GSK and Genmab Receive EU Authorization for Arzerra(tm) (ofatumumab) as First-Line Treatment for Chronic Lymphocytic Leukemia...USOTC:GNMSFGenmab A S (PK)
27/06/201420:27GlobeNewswire Inc.GSK and Genmab announce top-line results from a Phase III study of ofatumumab versus physicians' choice for bulky fludarabine...USOTC:GNMSFGenmab A S (PK)
04/06/201408:27GlobeNewswire Inc.Genmab Announces DuoBody and HexaBody Platform Collaboration With Undisclosed Biotechnology CompanyUSOTC:GNMSFGenmab A S (PK)
30/05/201417:04GlobeNewswire Inc.Genmab Announces Ofatumumab Development Plans in RRMS and NMOUSOTC:GNMSFGenmab A S (PK)
23/05/201415:21GlobeNewswire Inc.GSK and Genmab Receive CHMP Positive Opinion for Arzerra(tm) in Combination with Chlorambucil or Bendamustine as a First-line...USOTC:GNMSFGenmab A S (PK)
19/05/201420:21GlobeNewswire Inc.GSK and Genmab Announce Topline Results from a Pivotal Head to Head Study of Ofatumumab in Combination With Chemotherapy vs R...USOTC:GNMSFGenmab A S (PK)
07/05/201417:11GlobeNewswire Inc.Genmab Announces Financial Results for the First Quarter of 2014USOTC:GNMSFGenmab A S (PK)
01/05/201421:09GlobeNewswire Inc.Genmab Announces New Phase III Study of Daratumumab in Multiple Myeloma & Improves 2014 Financial GuidanceUSOTC:GNMSFGenmab A S (PK)
30/04/201413:11GlobeNewswire Inc.First Quarter 2014 Net Sales Figures for ArzerraUSOTC:GNMSFGenmab A S (PK)
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:USOTC:GNMSF

La tua Cronologia

POLO
WLUNAUSDT
Wrapped LUNA Token
LATK
GTPETH
TronGameGlobalPay
NASDAQ
FHPQVX
Limited Duration Fixed I...
BIT
P1IBS4
BNP Paribas Issuance
LSE
ARG
Argos Resources
BIT
F35281
Vontobel Financial Produ...
ASX
VLA
Viralytics
NASDAQI
EKG
First Trust Nasdaq Lux D...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network